News and Press Releases
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 10, 2025
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 9, 2025
ELRIG Announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025
Therapeutic Oligonucleotides 2025: Drugging the Undruggable takes place at AstraZeneca in Gothenburg, Sweden from 14–15 May 25 March 2025 -- Cambridge, UK -- ELRIG, a not-for-profit, volunteer-led organisation for the drug...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025
ELRIG Announces Drs Jue Wang and Robert Grundy as Keynote Speakers at Research & Innovation 2025
24 January 2025 -- Cambridge, UK -- The European Laboratory Research & Innovation Group (ELRIG), a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Research...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 24, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Paris voted the ‘heart of pharma’ in Europe
Pharmapack Europe research reveals Île-de-France is the second-best location in Europe for ‘drug manufacturing’ and to ‘start a biotech’ Paris, France – The global drug delivery and packaging industry arrives...
Category:
Posted: January 13, 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS
Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients Mitsubishi Tanabe Pharma Corporation...
Category: BioManufacturing, Drug Discovery
Posted: December 11, 2024
Dewpoint Therapeutics 451 D Street, Suite 104 Boston, MA 02210 USA
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
DRUG DISCOVERY 2024: CONNECTING MINDS, TRANSFORMING SCIENCE, EMPOWERING COMMUNITY
We are proud to be media partners of ELRIG's Drug Discovery 2024! Europe’s largest conference for the drug discovery community returns to London, with scientific tracks covering not only therapeutic...
Category: Drug Discovery
Posted: August 29, 2024
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness of VYNDAQEL (tafamidis) in Patients with Transthyretin Cardiac Amyloidosis
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. 6 August 2024 -- Walton Oaks, UK -- Pfizer Ltd today announced publication...
Category: Drug Discovery, Other, Pharmaceutical
Posted: August 8, 2024
Evotec and Pfizer collaborate to advance drug discovery in France
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases 11 July 2024, Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:...
Category: Drug Discovery
Posted: July 11, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Just – Evotec Biologics selected by US Department of Defence for Manufacturing Optimisation Programme
Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s manufacturing optimisation programme Manufacturing solution includes seamless integration of accelerated mAb drug development into...
Category: BioManufacturing
Posted: July 10, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
